Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis

Lisa Saiman, Yunhua Chen, Pablo San Gabriel, Charles Knirsch
Lisa Saiman
1Department of Pediatrics, Columbia University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: LS5@columbia.edu
Yunhua Chen
1Department of Pediatrics, Columbia University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo San Gabriel
1Department of Pediatrics, Columbia University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Knirsch
2Pfizer Pharmaceuticals, Inc., New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.46.4.1105-1107.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.

Cystic fibrosis (CF) is the most common autosomal recessive, life-shortening disease among Caucasians (3, 16). The unique predilection of Pseudomonas aeruginosa and Burkholderia cepacia complex for the CF lung has been well described (4), but other gram-negative bacilli, including Stenotrophomonas maltophilia and Alcaligenes xylosoxidans, are being recovered from CF patients with increasing frequency (1). While the impact of these potentially emerging pathogens on morbidity and mortality remains under study, there are limited therapeutic options available due to intrinsic and acquired resistance to antimicrobial agents.

There has been much interest recently in the treatment of CF patients with macrolide antibiotics (8, 12). In vitro, macrolide agents can inhibit the production of virulence factors by P. aeruginosa (13, 14, 23), including the production of alginate, the main component of the biofilm associated with chronic lung disease in CF (2, 7, 9, 10). Macrolides may be antiinflammatory and may decrease cytokine production by neutrophils, monocytes, and bronchial epithelial cells (6). Macrolides paired with other agents can have synergistic activity against P. aeruginosa (2). In this study, azithromycin and clarithromycin were paired with several antimicrobial agents to test synergistic activity against multidrug-resistant strains of P. aeruginosa, B. cepacia complex , S. maltophilia, and A. xylosoxidans isolated from CF patients.

The isolates tested were selected from strains sent to the CF Referral Center for Susceptibility and Synergy Testing at Columbia University (18). Fifty mucoid and 50 nonmucoid strains of P. aeruginosa from CF patients, 50 strains each of B. cepacia complex, S. maltophilia, and A. xylosoxidans from CF patients, and 50 strains of P. aeruginosa from non-CF patients (19) were studied. CF strains with different antimicrobial susceptibilities were selected (Table 1). To confirm identification to the species level, strains were placed on oxidative-fermentative, polymixin, bacitracin, lactose (OFPBL)-DNase and Mueller-Hinton agar plates (Remel, Lenexa, Kans.), and probed for the exotoxin A gene of P. aeruginosa as previously described (19, 20). The commercial identification assay API 20 NE (bioMérieux/Vitek, Hazelwood, Mo.) was used to identify A. xylosoxidans (20). To determine antimicrobial susceptibility, a broth microdilution assay (Microtech Medical Systems, Inc., Aurora, Colo.) was used to test 13 antimicrobial agents including azithromycin and clarithromycin. To determine synergy, checkerboard dilutions of pairs of antimicrobial agents in microtiter plates were also prepared commercially (Microtech). The following 12 combinations were tested in serial twofold dilutions: azithromycin (0.5 to 8 μg/ml)-tobramycin (1 to 8 μg/ml), azithromycin (0.5 to 8 μg/ml)-ciprofloxacin (0.5 to 4 μg/ml), azithromycin (0.5 to 8 μg/ml)-trovafloxacin (0.5 to 4 μg/ml), azithromycin (0.5 to 8 μg/ml)-ticarcillin-clavulanate (8 to 64 μg/ml), azithromycin (0.5 to 8 μg/ml)-ceftazidime (2 to 16 μg/ml), azithromycin (0.5 to 8 μg/ml)-meropenem (1 to 8 μg/ml), azithromycin (0.5 to 8 μg/ml)-doxycycline (1 to 8 μg/ml), azithromycin (0.5 to 8 μg/ml)-trimethoprim-sulfamethoxazole (0.5 to 4 μg/ml), clarithromycin (0.5 to 8 μg/ml)-tobramycin (1 to 8 μg/ml), clarithromycin (0.5 to 8 μg/ml)-ciprofloxacin (0.5 to 4 μg/ml), clarithromycin (0.5 to 8 μg/ml)-trovafloxacin (0.5 to 4 μg/ml), and clarithromycin (0.5 to 8 μg/ml)-ceftazidime (2 to 16 μg/ml). The fractional inhibitory concentration (FIC) was calculated as described previously (18); an FIC of <0.5 was considered synergistic and an FIC of 0.5 to <1.0 was considered additive. The same inoculum (105 CFU/ml) of a given isolate was used in the susceptibility studies and the synergy studies.

As expected, all strains were resistant to azithromycin and clarithromycin (the MIC at which 50% of isolates were inhibited was ≥512 μg/ml). However, synergistic and additive activities were noted when macrolide agents were paired with conventional antimicrobial agents (Table 2). This was particularly true for P. aeruginosa strains. Overall, combinations were more active against CF isolates than against non-CF isolates and more active against mucoid strains than against nonmucoid strains.

With the increasing life expectancy of CF patients, more courses of antibiotics are used with the adverse consequence of increasing antimicrobial resistance. During the past decade, no new antibiotics have been approved for the treatment of pathogens in CF patients. Thus, the CF community has been exploring the novel use of currently available agents such as aerosolized tobramycin (17) and, more recently, macrolide agents (8, 12).

Much of this interest stems from the use of macrolides in the treatment of diffuse panbronchiolitis (DPB), a disease seen primarily in Japanese adults (11, 21). DPB has several clinical features similar to those of CF including chronic, progressive lung disease caused by mucoid P. aeruginosa. DPB may be mild CF; patients with DPB do not have the common CFTR mutations seen in Caucasian patients with CF, but they do have mutations of the CFTR gene (K. Yoshimura, S. Iizuka, et al., Abstr. 2000 International Conference of the American Thoracic Society, Am. J. Respir. Crit. Care Med. 161:A77, 2000). For patients with DPB, the use of macrolides has been associated with marked improvement in morbidity and mortality (11, 21, 22). For patients with CF, small, open-label trials have demonstrated that either clarithromycin or azithromycin improved pulmonary function or increased body weight (M. I. Anstead, R. J. Kuhn, et al., Abstr. 13th North American Cystic Fibrosis Conference, Pediatr. Pulmonol., Suppl. 19, abstr. 421, 1999). A study currently under way in the United States (L. Saiman, personal communication) and another recently completed in the United Kingdom (A. Equi, A. Bush, et al., Abstr. 15th North American Cystic Fibrosis Conference, Pediatr. Pulmonol., Suppl. 22, abstr. 396, 2001) test the safety and efficacy of prolonged therapy with azithromycin in CF patients chronically infected with P. aeruginosa.

We confirmed the lack of activity of the macrolide agents azithromycin and clarithromycin against CF pathogens which included multidrug-resistant strains of P. aeruginosa, B. cepacia, S. maltophilia, and A. xylosoxidans. However, when they were paired with ceftazidime, quinolones, or agents that interfere with protein synthesis such as chloramphenicol, tetracycline, or tobramycin, modest synergistic and additive activitieswere observed. This compared favorably with the findings of our previous studies in which pairs of conventional agents inhibited between 10% (e.g., imipenem and amikacin) and 37% (e.g., piperacillin and tobramycin) of multidrug-resistant strains of P. aeruginosa (18).

There are several limitations to this study. In vitro activity may not predict in vivo efficacy, particularly for the synergy studies. Conventional susceptibility testing is an inadequate methodology for determining the nonbactericidal activities of macrolide agents. Finally, individual macrolide agents may not be comparable in their effects.

In conclusion, macrolide antibiotics may reduce the virulence factors of P. aeruginosa. The chronic, progressive lung disease of CF is due in part to the formation of a biofilm (10, 13), and the appearance of the mucoid phenotype of P. aeruginosa has been associated with clinical deterioration (5, 15). A strategy that could prevent or disrupt the biofilm within the CF lung could potentially reduce the bacterial burden, promote the activity of conventional antibiotics, and perhaps even prevent chronic infection.

View this table:
  • View inline
  • View popup
TABLE 1.

Antimicrobial susceptibility patterns of tested isolates

View this table:
  • View inline
  • View popup
TABLE 2.

Synergistic and additive effects of macrolide agents paired with conventional antimicrobial agents

ACKNOWLEDGMENTS

This work was supported by Pfizer Pharmaceuticals, Inc., and the U.S. CF Foundation.

FOOTNOTES

    • Received 23 August 2001.
    • Returned for modification 23 October 2001.
    • Accepted 20 December 2001.
  • Copyright © 2002 American Society for Microbiology

REFERENCES

  1. 1.↵
    Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis.27:158-163.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Dupont, M., and J. Lapointe. 1995. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum onto Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampin. J. Antimicrob. Chemother.36:231-236.
    OpenUrlCrossRefPubMed
  3. 3.↵
    FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr.122:1-9.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Gilligan, P. H. 1991. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev.4:35-51.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Henry, R. L., C. M. Mellis, and L. Petrovic. 1992. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol.12:158-161.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Ichikawa, Y., H. Ninomiya, H. Koga, M. Tanaka, M. Kinoshita, N. Tokunaga, T. Yano, and K. Oizumi. 1992. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis.146:196-203.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Ichimiya, Y., T. Yamasaki, and T. Nasu. 1994. In vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J. Antimicrob. Chemother.34:331-341.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Jaffe, A., J. Francis, M. Rosenthal, and A. Bush. 1998. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet351:420.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Kobayashi, H. 1995. Biofilm disease: its clinical manifestations and therapeutic possibilities of macrolides. Am. J. Med.99(Suppl. 6A):26-30.
    OpenUrl
  10. 10.↵
    Kondoh, K., M. Hashiba, and S. Baba. 1996. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol.S525:56-60.
  11. 11.↵
    Kudoh, S., A. Azuma, M. Yamamoto, T. Izumi, and M. Ando. 1998. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med.157:1829-1832.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Labro, M. T. 1998. Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother.41:37-46.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Mizukane, R., Y. Hirakata, M. Kaku, Y. Ishii, N. Furuya, K. Ishida, H. Koga, S. Kohno, and K. Yamaguchi. 1994. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother.38:528-533.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Molinari, G., C. A. Guzman, A. Pesce, and G. C. Schito. 1993. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother.31:681-688.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Parad, R. B., C. J. Gerard, D. Zurakowski, D. P. Nichols, and G. B. Pier. 1999. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect. Immun.67:4744-4750.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Ramsey, B. W. 1996. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med.335:179-188.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med.340:23-30.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolates from CF patients, including transplant candidates. Clin. Infect. Dis.23:532-537.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Saiman, L., J. A. Burns, S. Whittier, S. Krzewinski, S. A. Marshall, and R. A. Jones. 1999. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J. Clin. Microbiol.37:2987-2991.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Saiman, L., Y. Chen, S. Tabibi, P. San Gabriel, J. Zhou, Z. Liu, L. Lai, and S. Whittier. 2001. Identification and antimicrobial susceptibility testing of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol.39:3942-3945.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Sugiyama, Y. 1993. Diffuse panbronchiolitis. Clin. Chest Med.14:765-772.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    Tanimoto, H. 1991. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot. Chemother. Rev.44:94-98.
    OpenUrl
  23. 23.↵
    Tateda, K., Y. Ishii, T. Matsumoto, N. Furuya, M. Nagashima, T. Matsunaga, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1996. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother.40:2271-2275.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis
Lisa Saiman, Yunhua Chen, Pablo San Gabriel, Charles Knirsch
Antimicrobial Agents and Chemotherapy Apr 2002, 46 (4) 1105-1107; DOI: 10.1128/AAC.46.4.1105-1107.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis
Lisa Saiman, Yunhua Chen, Pablo San Gabriel, Charles Knirsch
Antimicrobial Agents and Chemotherapy Apr 2002, 46 (4) 1105-1107; DOI: 10.1128/AAC.46.4.1105-1107.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Alcaligenes
Anti-Bacterial Agents
Burkholderia cepacia
cystic fibrosis
Pseudomonas aeruginosa
Stenotrophomonas maltophilia

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596